Lilly to file for next-gen obesity drug approval in early 2027
Go back to Lilly to file for next-gen obesity drug approval in early 2027| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1226.11 -5.83 (0.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1231.94 | 52 Week High | $88.16 | |||
| Open | $1230.65 | 52 Week Low | $67.88 | |||
| Day High | $1238.00 | P/E | 283.82 | |||
| Day Low | $1210.01 | EPS | $4.32 | |||
| Volume | 690,341 | |||||
| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 47.20 -0.53 (1.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $47.73 | 52 Week High | $59.00 | |||
| Open | $47.45 | 52 Week Low | $32.80 | |||
| Day High | $47.67 | P/E | N/A | |||
| Day Low | $47.11 | EPS | $0.00 | |||
| Volume | 3,183,648 | |||||
